Aileron Therapeutics Inc
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that ha… Read more
Aileron Therapeutics Inc (ALRN) - Total Liabilities
Latest total liabilities as of September 2024: $53.99 Million USD
Based on the latest financial reports, Aileron Therapeutics Inc (ALRN) has total liabilities worth $53.99 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aileron Therapeutics Inc - Total Liabilities Trend (2014–2023)
This chart illustrates how Aileron Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Aileron Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Aileron Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Northfield Capital Corporation
V:NFD-A
|
Canada | CA$22.64 Million |
|
Nonthavej Hospital Public Company Limited
BK:NTV
|
Thailand | ฿366.81 Million |
|
Neontech Co. Ltd
KQ:306620
|
Korea | ₩105.48 Billion |
|
AVE S.A.
AT:AVE
|
Greece | €45.63 Million |
|
Travelzoo
NASDAQ:TZOO
|
USA | $47.53 Million |
|
LIWANLI Innovation Co Ltd
TW:3054
|
Taiwan | NT$32.86 Million |
|
Goodness Growth Holdings Inc
OTCQX:GDNSF
|
USA | $432.61 Million |
|
Wave Electronics Co. Ltd
KQ:095270
|
Korea | ₩49.79 Billion |
Liability Composition Analysis (2014–2023)
This chart breaks down Aileron Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aileron Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aileron Therapeutics Inc (2014–2023)
The table below shows the annual total liabilities of Aileron Therapeutics Inc from 2014 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $99.12 Million | +2829.11% |
| 2022-12-31 | $3.38 Million | -26.07% |
| 2021-12-31 | $4.58 Million | +9.52% |
| 2020-12-31 | $4.18 Million | -59.91% |
| 2019-12-31 | $10.43 Million | -2.68% |
| 2018-12-31 | $10.71 Million | +119.01% |
| 2017-12-31 | $4.89 Million | -96.35% |
| 2016-12-31 | $133.83 Million | +33.48% |
| 2015-12-31 | $100.26 Million | +4539.47% |
| 2014-12-31 | $2.16 Million | -- |